All News

Amber Draper, PharmD, BCOP, clinical pharmacist, Winship Cancer Institute in Georgia discusses current recommendations for colon cancer screening. This video was filmed at the 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, Texas.

In addition to first-line treatment of blepharospasm, the drug is indicated for adult patients with cervical dystonia, upper limb spasticity, and chronic sialorrhea, or excessive drooling.

In 2016, an estimated 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women, according a CDC report.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Procedure uses small incisions and a miniature video camera to reduce the risk of complications from surgery for lung cancer.

Top news of the day from across the health care landscape.

The FDA's approval was based on 6-month and 1-year results from the PANORAMA clinical trial.

Kaposi sarcoma is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels, and most commonly affects individuals with HIV.

The novel intravenous immune globulin (IVIG) product is indicated for individuals with primary humoral immunodeficiency disease (PIDD), which includes X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiency.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

From 2018 to 2040, the number of patients who will need chemotherapy each year is estimated to rise from 9.8 million to 15 million.

Promacta (eltrombopag, Novartis) 12.5 mg for oral suspension was distributed nationwide through specialty pharmacies.

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.

Top news of the day from across the health care landscape.

JK is experiencing gastrointestinal effects. What could be the cause?

Novartis has issued a voluntary recall of 3 lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level, due to a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.

As The Pharmacy Sage, I often write about solving your most brutal problems by asking the right questions.

Pharmacists can counsel patients on the best ways to reduce the risk of skin cancer.

Patients with HCC who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib are eligible for this treatment.

Ramucirumab (Cyramza, Eli Lilly) is approved as a single agent in patients with elevated alpha fetoprotein who have been previously treated with sorafenib.

The designation is intended to expedite the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints.

The final guidance will provide clarity for developers who want to demonstrate that their proposed biological products meet the statutory interchangeability standard under the Public Health Service Act.

An agreement between the US Department of Health and Human Services and Gilead will provide HIV prevention drugs to uninsured individuals who are at risk.

The pathway is intended to help patients by making more treatment options available through biosimilar and interchangeable products.

This product is a generic version of Genentech's Tarceva.

Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

The House investigational hearing drew testimony from health care industry experts representing insurers, patient advocacy groups, and pharmaceutical companies.

Compared with interferon beta-1a, ozanimod reduced less cortical grey matter volume in patients with relapsing forms of multiple sclerosis.